We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Computer-aided Therapeutics in Treating Autoimmune Encephalitis—Reply

Bastien Joubert, MD1,2; Pierre Paoletti, PhD3; Jérôme Honnorat, MD, PhD1,2,4,5
[+] Author Affiliations
1University Lyon 1, University Lyon, Lyon, France
2Hospices Civils de Lyon, Neuro-oncologie, Hôpital Neurologique, Bron, France
3Institut de Biologie de l’Ecole Normale Supérieure (IBENS), Ecole Normale Supérieure, CNRS UMR 8197, INSERM U1024, Paris, France
4Centre National de Référence pour les Syndromes Neurologiques Paranéoplasiques, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France
5Lyon Neuroscience Research Center, Neuro-Oncology and Neuro-Inflammation Team, INSERM, UMR-S1028, CNRS, UMR-5292, Lyon, France
JAMA Neurol. 2016;73(1):128. doi:10.1001/jamaneurol.2015.3519.
Text Size: A A A
Published online


In Reply We read with interest Dr Avasarala’s letter in which he raised the need for more specific and efficient treatment in antibody-mediated encephalitides. Indeed, the development of adequate therapeutic approaches is hampered both by the lack of disease-specific drugs and because the rarity of those disorders prevents controlled treatment studies. Dr Avasarala proposes that the growing knowledge about the 3-dimensional structure of the involved antigens (eg, the N-methyl-D-aspartate receptor [NMDAR] or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor [AMPAR]) should be used to design peptides that could serve as decoys for pathogenic antibodies.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





January 1, 2016
Jagannadha Avasarala, MD, PhD
1Division of Neurology, Neuroscience Associates, Department of Medicine, Greenville Health System, Greenville, South Carolina
JAMA Neurol. 2016;73(1):127-128. doi:10.1001/jamaneurol.2015.3516.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...